Kiniksa Pharmaceuticals International Plc Q3 FY2025 earnings call

Sanj Patel's Remarks - Year-to-date, Kiniksa has advanced its commercial business and clinical development portfolio. ARCALYST revenue has grown, and they raised full-year net sales guidance. KPL-387 has Orphan Drug Designation for pericarditis. - Maintained a robust financial position without relying on capital markets. ### Ross Moat's Remarks - ARCALYST's commercial execution: new patient enrollments grew, prescriber count increased, patients staying on therapy longer. - Commercial organization focused on evolving treatment landscape for recurrent pericarditis. - Excited about KPL-387's potential as a monthly subcutaneous dose auto-injector for recurrent pericarditis. ### Mark Ragosa's Remarks - Third quarter ARCALYST revenue grew 61% year-over-year to $180.9 million. - Operating expenses grew 29% year-over-year, but net income improved. - ARCALYST collaboration profit grew 118% year-over-year. - Cash balance increased to $352.1 million in Q3.

In the third quarter, ARCALYST revenue grew to $180.9 million, representing a 61% year-over-year increase. This growth is driven by the increasing adoption of IL-1 alpha and beta inhibition with ARCALYST for recurrent pericarditis. ARCALYST contributes significantly to the company's revenue, with its revenue in Q3 being a key driver of the overall financial performance.

- Raised full-year net sales guidance to between $670 million to $675 million from previous $625 million to $640 million. ### - ARCALYST net sales guidance tightened to between $670 million and $675 million from prior $625 million to $640 million. ### - Expect data from Phase II dose focusing portion of Phase II/III trial for KPL-387 in second half of 2026.

- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from statements. These risks and uncertainties can be found in SEC filings under 'Risk Factors'.

Q: Could you comment on patient and physician feedback on ARCALYST duration?

A: John Paolini and Ross Moat discussed that median duration of disease is 3 years, continued treatment without interruption led to 99.5% reduction in event rates. Patients and healthcare professionals have given positive feedback as ARCALYST is designed for long-term treatment of a chronic debilitating disease.

Q: How have you incorporated updated ACC guidelines into marketing efforts?

A: John Paolini mentioned ACC guidelines affirm IL-1 pathway inhibition as second line after NSAIDs and colchicine. Ross Moat stated they utilize the guidance in promotional materials and it affirms their existing messaging.

Q: What drove strong increase in number of prescribers and proportion of recurrent pericarditis patients seen by prescribers?

A: Ross Moat said Q3 had highest new prescribers, due to more confidence, awareness, ACC guidance. Also, 3,800+ prescribers with significant patient population coverage but still opportunity to grow.